Financial Results for the 2nd Quarter of the Year Ending March 31, 2012 <Supplement>

As of October 31, 2011

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

Table of Contents

1 Summary of Financial Results for the 2nd Quarter of FY2011 Ending March 31, 2012 and Forecasts for FY2011

(Amounts less than ¥100 million are rounded down.)

1. Summary of Financial Results for the 2nd Quarter of FY2011

[Billion yen]

Net Sales	200.3	Y-on-Y	(4.3)	(2.1 %)
Pharmaceuticals	195.4	Y-on-Y	(4.4)	(2.2 %)
Other Businesse	4.9	Y-on-Y	0.0	2.0 %

In the pharmaceuticals segment, net sales were ¥195.4 billion, down 2.2%, or ¥4.4 billion, year-on-year.
Although favorable sales were recorded by such products as Remicade, an anti-TNFα monoclonal antibody; Talion, a treatment for allergic disorders; and Maintate, a selective β1 antagonist, there was a rebound from a temporary increase in orders that was recorded at the end of the previous fiscal year due to the influence of the Great East Japan Earthquake, which occurred in March. As a result, the domestic sales of ethical drugs were ¥175.6 billion, down 1.9%, year-on-year.
Overseas sales of ethical drugs were down 19.0%, year-on-year, to ¥9.1 billion, due to the poor export sales.
Sales of others in pharmaceuticals increased 17.7%, year-on-year, to ¥7.6 billion, due to the increase in royalty revenue from Gilenya.

The Principal Products and Businesses in Each Business Segment
Pharmaceuticals: Ethical drugs, over-the-counter-drugs
Other businesses: Fine chemicals, real-estate leasing, information services, advertising, etc

[Billion yen]

Operating Incom	36.0	Y-on-Y	(4.1)	(10.2 %)

Operating income decreased 10.2%, or ¥4.1 billion, year-on-year, to ¥36.0 billion.
Gross profit declined ¥0.9 billion, year-on-year to ¥125.9 billion, due to decrease of ¥4.3 billion in net sales. Cost of sales ratio decreased 0.8 percentage points to 37.2%.
SG&A expenses were up 3.7%, or ¥3.1 billion, year-on-year, to ¥89.8 billion, due primarily to increase in R&D expenses. R&D expenses were up 3.3%, or ¥1.0 billion, year-on-year, to ¥33.5 billion, or 16.8% of net sales.

[Billion yen]

Ordinary Income	36.3	Y-on-Y	(4.1)	(10.1 %)

Net Income	19.9	Y-on-Y	(2.7)	(12.1 %)

Due to decrease in operating income, ordinary income was down 10.1%, or ¥4.1 billion, year-on-year, to ¥36.3 billion, and net income was down 12.1%, or ¥2.7 billion, year-on-year, to ¥19.9 billion.
Extraordinary losses were ¥3.2 billion, including loss on impairment of fixed assets of ¥2.9 billion. In the previous fiscal year, the Company recorded extraordinary losses of ¥3.7 billion, such as loss on valuation of investment in securities of ¥2.4 billion.

2. Summary of Forecasts for FY2011

[Billion yen]

Net Sales	405.0	Y-on-Y	(4.5)	(1.1 %)
Operating Incom	68.0	Y-on-Y	(8.5)	(11.2 %)
Ordinary Income	68.0	Y-on-Y	(8.6)	(11.3 %)
Net Income	37.5	Y-on-Y	(0.2)	(0.7 %)

3. Dividends

	FY2011 (Estimate)		FY2010	
	End of 1st Half	For the Year	End of 1st Half	For the Year
Dividends per Share (¥)	15	30	14	28
Dividends Payout Ratio	33.7%	35.4%	32.9%	

Note: The dividend payout ratio is calculated using net income (less amortization of goodwill) and dividends.

2 Consolidated Financial Indicators for 2nd Quarter of FY2011

(Amounts less than ¥100 million are rounded down.)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	1st Half of FY2011	Y-on-Y			Comparison to Forecasts		
		1st Half of FY2010	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %
Net sales	**200.3**	204.6	(4.3)	(2.1)	199.0	1.3	0.7
Cost of sales	**74.4**	77.8	(3.3)	(4.4)	75.5	(1.0)	(1.4)
Sales cost ratio	**37.2%**	38.0%			37.9%		
Gross operation profit	**125.9**	126.8	(0.9)	(0.7)	123.5	2.4	2.0
SG&A expenses	**89.8**	86.6	3.1	3.7	91.5	(1.6)	(1.8)
% of net sales	**44.9%**	42.4%			46.0%		
Operating income	**36.0**	40.1	(4.1)	(10.2)	32.0	4.0	12.7
Ordinary income	**36.3**	40.4	(4.1)	(10.1)	32.0	4.3	13.7
Extraordinary income	**-**	0.4	(0.4)	-	-	-	-
Extraordinary loss	**3.2**	3.7	(0.4)	-	3.5	(0.2)	(5.9)
Net income	**19.9**	22.7	(2.7)	(12.1)	16.5	3.4	21.0

(2) Sales by Business Segments

[Billion yen]

	1st Half of FY2011	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		1st Half of FY2010	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %	
Pharmaceuticals	**195.4**	199.8	(4.4)	(2.2)	194.0	1.4	0.7	Ethical drugs domestic sales (3.4) Ethical drugs overseas sales (2.1) Contracted manufacturing products (0.4) Licensing fee, etc. 1.5 See page 5, "Sales of Main Products"
% Composition	**97.5%**	97.6%			97.5%			
[Domestic]	**[183.5]**	[187.4]	[(3.9)]	[(2.1)]	[183.0]	[0.5]	[0.3]	
[Overseas]	**[11.8]**	[12.3]	[(0.5)]	[(4.1)]	[11.0]	[0.8]	[7.7]	
Others	**4.9**	4.8	0.0	2.0	5.0	0.0	(1.1)	
% Composition	**2.5%**	2.4%			2.5%			
[Domestic]	**[3.5]**	[3.4]	[0.1]	[3.3]	[3.5]	[0.0]	[2.7]	
[Overseas]	**[1.3]**	[1.3]	[0.0]	[(1.4)]	[1.5]	[(0.1)]	[(10.1)]	
Total	**200.3**	204.6	(4.3)	(2.1)	199.0	1.3	0.7	Overseas sales ratio 1st half of FY2010: 6.7% 1st half of FY2011: 6.6% Average exchange rate 1st half of FY2010, 1$= ¥91.02 1st half of FY2011, 1$= ¥81.78
% Composition	**100.0%**	100.0%			100.0%			
[Domestic]	**[187.1]**	[190.9]	[(3.7)]	[(2.0)]	[186.5]	[0.6]	[0.4]	
[Overseas]	**[13.1]**	[13.7]	[(0.5)]	[(3.8)]	[12.5]	[0.6]	[5.6]	

(3) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	1st Half of FY2011	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		1st Half of FY2010	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %	
Cost of sales	**74.4**	77.8	(3.3)	(4.4)	75.5	(1.0)	(1.4)	Sales cost ratio is improved according to the price cuts of the imported raw materials by the strong yen and the increase of the royalty revenues, etc.
% of Net sales	**37.2%**	38.0%			37.9%			
SG&A expenses	**89.8**	86.6	3.1	3.7	91.5	(1.6)	(1.8)	
% of Net sales	**44.9%**	42.4%			46.0%			
R&D expenses	**33.5**	32.4	1.0	3.3	34.5	(0.9)	(2.7)	Increase according to the progress of the late development stage product, etc.
% of Net sales	**16.8%**	15.9%			17.3%			
Except R&D expenses	**56.3**	54.2	2.1	3.9	57.0	(0.6)	(1.2)	
Labor cost	**25.9**	25.8	0.0	0.4	25.5	0.4	1.6	
Amortization of goodwill*2	**5.0**	5.0	0.0	(0.1)	5.0	0.0	1.3	
Others	**25.3**	23.3	2.0	8.7	26.5	(1.1)	(4.4)	
Total labor cost	**44.4**	44.0	0.3	0.8	44.5	0.0	(0.2)	

*1: Published forecasts announced on Jul. 29, 2011 in the financial results for 1st quarter of FY2011

*2: Clear off 150.5 billion yen within 15 years.

(4) Non-operating Income and Loss

[Billion yen]

	1st Half of FY2011	1st Half of FY2010	Increase (Decrease)	Notes
Non-operating income	**2.0**	1.7	0.2	
Interest income	**0.7**	0.8	0.0	
Dividend income	**0.4**	0.4	0.0	
Equity in earnings of income	**0.1**	-	0.1	
Others	**0.6**	0.4	0.1	
Non-operating expenses	**1.7**	1.4	0.2	
Foreign exchange loss	**0.4**	0.2	0.1	
Losses on disposal of property, plant and equipment	**0.2**	0.1	0.0	
Tax and dues	**0.2**	0.2	0.0	
Donations	**0.1**	0.1	0.0	
Others	**0.6**	0.6	0.0	

(5) Extraordinary Income and Loss

[Billion yen]

	1st Half of FY2011	1st Half of FY2010	Increase (Decrease)	Notes
Exordinary income	**-**	0.4	(0.4)	
Gains on sale of property, plant and equipment	**-**	0.2	(0.2)	
Reversal of past year patent royalties	**-**	0.1	(0.1)	
Extraordinary Loss	**3.2**	3.7	(0.4)	
Loss on valuation of investment in securities	**0.0**	2.4	(2.3)	
Impairment loss	**2.9**	-	2.9	Sanban-cho office, Tokyo
Loss related to business suspension	**-**	0.7	(0.7)	FY2010: Expenses related to business suspension of BIPHA Corp.
Special retirement expenses	**-**	0.4	(0.4)	FY2010: Additional retirement expenses accompanied with employment transfer
Restructuring expenses	**-**	0.1	(0.1)	
Others	**0.3**	-	0.3	

(6) Taxes

[Billion yen]

	1st Half of FY2011	1st Half of FY2010	Increase (Decrease)	Notes
Income before income taxes and minority interests	**33.0**	37.1	(4.0)	
Income taxes-current	**10.4**	12.8	(2.4)	
Income taxes-deferred	**2.5**	1.7	0.8	
Minority interests	**0.1**	(0.1)	0.3	
Net Income	**19.9**	22.7	(2.7)	

	1st half of FY2011	1st half of FY2010
Statutory tax rate	40.6%	40.6%
Adjustment		
Non-deductible expenses	2.4%	2.1%
Non-taxable devidend income, etc.	(3.1%)	(2.7%)
Adjustment for per capital inhabitants tax	0.2%	0.2%
Special deduction for R&D expenses	(9.4%)	(8.6%)
Amortization of goodwil	6.1%	5.5%
Elimination of dividends upon consolidation	2.8%	2.4%
Others	(0.4%)	(0.1%)
Actual tax rate	39.2%	39.4%

(7) Sales of Main Products

[Billion yen]

	1st Half of FY2010	Y-on-Y			Comparison to Forecasts		
		1st Half of FY2010	Increase (Decrease)	Change %	Forecasts *1	Increase (Decrease)	Change %
Ethical drugs	**192.5**	196.9	(4.4)	(2.3)	191.5	1.0	0.5
Ethical drugs domestic sales	**175.6**	179.1	(3.4)	(1.9)	176.5	(0.8)	(0.5)
Remicade	**32.0**	29.3	2.7	9.3	-	-	-
Radicut	**12.7**	14.2	(1.4)	(10.5)	-	-	-
Ceredist	**8.9**	8.9	0.0	(0.6)	-	-	-
Anplag	**7.7**	8.2	(0.5)	(6.7)	-	-	-
Talion	**5.3**	4.7	0.5	12.0	-	-	-
Urso	**7.2**	7.7	(0.5)	(6.6)	-	-	-
Maintate	**6.5**	5.9	0.6	10.4	-	-	-
Kremezin *2	**6.1**	-	6.1	-	-	-	-
Depas	**5.4**	5.7	(0.2)	(4.9)	-	-	-
Venoglobulin IH	**5.0**	4.5	0.4	10.7	-	-	-
Herbesser	**4.3**	4.8	(0.5)	(10.4)	-	-	-
Tanatril	**4.2**	4.9	(0.7)	(14.4)	-	-	-
Liple	**3.1**	3.7	(0.5)	(15.5)	-	-	-
Sermion	**2.8**	3.3	(0.4)	(13.9)	-	-	-
Neuart	**2.5**	2.7	(0.1)	(7.1)	-	-	-
Omeprason	**2.1**	2.4	(0.3)	(13.4)	-	-	-
BIKEN Products [Vaccine]	**15.1**	15.0	0.0	0.2	-	-	-
Mearubik	**6.2**	7.5	(1.3)	(17.3)	-	-	-
JEVIK V	**4.8**	3.7	1.1	31.9	-	-	-
Influenza	**2.3**	1.9	0.3	19.9	-	-	-
Tanabe Seiyaku Hanbai Products *3	**8.2**	5.4	2.7	51.7	-	-	-
Ethical drugs overseas sales	**9.1**	11.2	(2.1)	(19.0)	8.5	0.6	7.6
Herbesser	**2.2**	2.4	(0.1)	(5.7)	2.2	0.0	0.4
Argatroban (Novastan)	**1.6**	1.8	(0.2)	(10.9)	1.5	0.1	7.1
Tanatril	**0.8**	0.9	(0.1)	(10.3)	0.8	0.0	(1.0)
Vaccine	**0.9**	0.6	0.2	40.8	0.9	0.0	3.6
Contracted manufacturing products *4	**4.7**	5.2	(0.4)	(8.3)	4.0	0.7	19.6
Lincensing Fee, etc.	**2.9**	1.3	1.5	120.8	2.5	0.4	16.0
OTC products	**2.8**	2.8	0.0	0.5	2.5	0.3	15.4
Total Pharmaceuticals	**195.4**	199.8	(4.4)	(2.2)	194.0	1.4	0.7

*1: Published forecasts announced on July 29, 2011 in the financial results for 1st quarter of FY2011.

*2: In FY2010, Daiichi Sankyo sold Kremezin on consignment from MTPC. We recorded amount of money we sold Kremezin to Daiichi Sankyo in "ethical drugs domestic sales" in FY2010, however, we do not disclose this sales.

*3: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*4: Active pharmaceutical ingredients and others ordered by other companies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of Q2 FY2010	Composition %	End of FY2009	Increase (Decrease)	Notes
Total Aseets	**815.0**	**100.0**	818.7	(3.6)	
Current Assets	**401.2**	**49.2**	391.5	9.6	
Cash and deposits	**15.7**	**1.9**	27.4	(11.7)	See Page 7, (2) Cash Flows Statement
Marketable securities	**63.0**	**7.7**	84.7	(21.7)	Decrease of negotiable deposits and government bond, etc
Notes and accounts receivable*1	**127.4**	**15.6**	128.3	(0.8)	
[Months/Revolution]	**[3.82]**		[3.76]	[0.06]	
Inventories	**83.9**	**10.3**	77.7	6.2	Increase according to rebound from temporary increase in orders after the Great East Japan Earthquake.
Deposits	**96.5**	**11.8**	56.3	40.2	Increase according to a change of composition ratio for fund management
Deferred income taxes	**10.9**	**1.3**	12.5	(1.5)	
Others	**3.4**	**0.4**	4.4	(0.9)	
Fixed Assets	**413.8**	**50.8**	427.1	(13.3)	
Property, plant and equipment	**107.9**	**13.2**	113.5	(5.5)	Investment for plant and equipment, 2.8; Depreciation, (5.3); Impairment of Sanban-cho
Intangible fixed assets	**114.0**	**14.0**	119.2	(5.1)	Investment for information system, 0.3; Amortization of goodwill, (5.0); Depreciation, (0.5)
Investment in securities	**121.0**	**14.8**	127.6	(6.5)	Decrease of government bond, etc
Prepaid pension expenses	**41.2**	**5.1**	40.4	0.8	
Other investments	**29.5**	**3.6**	26.3	3.2	
Total Liabilities	**107.7**	**13.2**	122.7	(14.9)	
Current Liabilities	**75.9**	**9.3**	87.7	(11.8)	
Notes and accounts payable*2	**32.4**	**4.0**	29.6	2.8	Increase in debts for vaccine, etc
Short-term debt	**2.1**	**0.3**	2.8	(0.7)	
Accrued payable	**13.3**	**1.6**	20.3	(7.0)	Decrease according to payment of account payable for equipment
Income taxes payable	**10.3**	**1.3**	15.2	(4.8)	
Other current liabilities	**17.5**	**2.2**	19.6	(2.0)	
Long-term Liabilities	**31.8**	**3.9**	35.0	(3.1)	
Deferred income taxes	**10.4**	**1.3**	11.4	(0.9)	
Accrued retirement benefits for employees	**11.2**	**1.4**	11.8	(0.6)	
Reserve for health management allowances for HIV compensation	**1.4**	**0.2**	1.5	0.0	
Reserve for health management allowances for SMON compensation	**3.5**	**0.4**	3.8	(0.2)	
Reserve for HCV litigation	**2.9**	**0.4**	4.6	(1.7)	Reversal accompanied with payment of the settlement
Other long-term liabilities	**2.1**	**0.3**	1.7	0.4	
Net Assets	**707.2**	**86.8**	695.9	11.3	
Shareholders' equity	**714.3**	**87.6**	702.2	12.1	
Common stock	**50.0**	**6.1**	50.0	-	
Capital surplus	**451.1**	**55.4**	451.1	-	
Retained earnings	**213.5**	**26.2**	201.4	12.1	Net income, 19.9; Payment for dividends, (7.8)
Teasury stock, at cost	**(0.4)**	**0.0**	(0.4)	-	
Accumulated other comprehensive loss	**(12.8)**	**(1.6)**	(12.0)	(0.8)	
Unrealized holding (losses) gains on securities	**(3.1)**	**(0.4)**	(2.7)	(0.4)	
Deffered (losses) gains on hedges	**(1.6)**	**(0.2)**	(1.0)	(0.6)	
Translation adjustments	**(8.0)**	**(1.0)**	(8.2)	0.2	
Minority interests	**5.8**	**0.7**	5.7	0.0	

*1: Note and accounts receivable = Bills + Accounts receivable

*2: Note and account payable=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	1st Half of FY2011	1st Half of FY2010	Increase (Decrease)	FY2010
Cash and cash equivalents at beginning of year	**97.8**	62.9	34.9	62.9
Cash flows from operating activities	**16.3**	32.9	(16.5)	59.0
Income before income taxes and minority interests	**33.0**	37.1	(4.0)	64.1
Depreciation and amortization	**5.8**	6.0	(0.1)	12.4
Impairment loss	**2.9**	0.0	2.9	0.8
Amortization of goodwill	**5.0**	5.0	0.0	10.1
Increase (decrease) in accrued retirement benefit for employees	**(0.6)**	(0.6)	0.0	(1.2)
Decrease (increase) in prepaid pension expenses	**(0.8)**	(1.8)	1.0	(3.7)
Increase (decease) in reserve for HCV litigation	**(1.7)**	(3.2)	1.5	(6.0)
Increase (decrease) in allowance for disaster	**-**	-	-	1.5
Interest and dividend income	**(1.1)**	(1.2)	0.0	(2.3)
Loss (gain) on sales of investments in securities	**0.0**	2.4	(2.3)	8.0
Decrease(increase) in notes and accounts receivable, trade	**0.9**	(0.9)	1.9	(2.5)
Decrease (increase) in inventories	**(6.1)**	(4.1)	(2.0)	(4.7)
Increase (decrease) in notes and accounts payable, trade	**2.7**	9.2	(6.4)	2.4
Increase(decrease) in accured expenses	**(3.6)**	(6.1)	2.4	(2.1)
Interest and dividends received	**1.2**	1.3	(0.1)	2.5
Income taxes paid	**(15.2)**	(10.3)	(4.9)	(22.2)
Other, net	**(6.0)**	0.2	(6.3)	2.0
Cash flows from investing activities	**(44.5)**	(24.8)	(19.7)	(7.6)
Purchase/sales etc. of marketable securities	**28.7**	4.0	24.6	25.7
Increase/decrease in time deposits	**8.8**	0.6	8.2	(0.9)
Increase in deposits	**(76.5)**	-	(76.5)	-
Increase/decrease in long-term deposits	**(0.4)**	0.0	(0.4)	0.0
Purchase/sales of property, plant and equipment	**(6.0)**	(3.9)	(2.0)	(7.0)
Purchase of intangible fixed assets	**(0.4)**	(0.3)	0.0	(0.7)
Purchase/sales of investment in securities	**1.2**	(25.3)	26.6	(24.7)
Other, net	**0.0**	0.0	0.0	0.0
Cash flows from financing activities	**(8.6)**	(7.7)	(0.8)	(15.4)
Increase (decrease) in short-term debt, net	**(0.7)**	0.2	(0.9)	0.4
Repayment of long-term loans debt	**-**	0.0	0.0	0.0
Cash dividends paid	**(7.8)**	(7.8)	0.0	(15.7)
Other, net	**0.0**	(0.1)	0.0	(0.1)
Effect of exchange rate change on cash and cash equivalents	**0.0**	(0.7)	0.7	(1.1)
Net increase (decrease) in cash and cash equivalents	**(36.7)**	(0.4)	(36.3)	34.8
Increase (decrease) in cash and cash equivalent resulting from merger with unconsolidated subsidiaries	**-**	0.0	0.0	0.0
Increase in cash and cash equivalents resulting from inclusion of a consolidated subsidiary	**-**	0.0	0.0	0.0
Cash and cash equivalents at end of year	**61.1**	62.5	(1.4)	97.8

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	1st Half of FY2011	1st Half of FY2010	FY2010
Cash and time deposits	15.7	24.9	27.4
Time deposits maturing after three months	(2.7)	(9.4)	(11.5)
Short-term investments in marketable securities maturing within three months of acquisition	27.9	8.0	25.4
Cash and cash equivalents included in short-term loans receivable*	0.1	0.0	0.1
Cash and cash equivalents included in deposits	20.0	39.0	56.3
Cash and cash equivalents in the consolidated statements of cash flows	61.1	62.5	97.8

*: Short-term loans are included in "Others, Current Assets" on "2-(1) Balance Sheet" (page 6).

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

	1st Half of FY2011	1st Half of FY2010	Increase (Decrease)	FY2010
Investment in property, plant and equipment /occuring basis	2.8	3.9	(1.0)	10.1
Investment in information systems/occuring basis	0.3	0.3	0.0	0.8

[Billion yen]

Major investment in property, plant and equipment in 1st half of FY2011		Major investment in development of information systems in 1st half of FY2011	
Mitsubishi Tanabe Pharma	1.1	Mitsubishi Tanabe Pharma	0.3
Mitsubishi Tanabe Pharma Factory	0.8		
[Manufacturing facilities at Ashikaga Plant]	[0.1]		
Benesis	0.6		
[Manufacturing facilities at Kyoto Plant]	[0.4]		

(4) Depreciation Costs

[Billion yen]

	1st Half of FY2011	1st Half of FY2010	Increase (Decrease)	FY2010
Property, plant and equipment	5.3	5.4	(0.1)	11.3
Intangible fixed assets	0.5	0.5	0.0	1.0

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

[Billion yen]

	Companies	Benesis Corporation	Mitsubishi Tanabe Pharma Factory Ltd.	Mitsubishi Tanabe Pharma Korea Co., Ltd.	Mitsubishi Pharma (Guangzhou) Co., Ltd.	Tianjin Tanabe Seiyaku Co., Ltd.
	Fiscal Year	End of Mar.	End of Mar.	End of Dec.	End of Dec.	End of Dec.
Net Sales	1st Half of FY2011	10.9	27.3	1.8	0.0	1.0
	FY2010	18.2	53.0	3.7	2.2	2.0
	1st Half of FY2010	9.8	26.7	1.9	1.3	1.0
Operating Income	1st Half of FY2011	2.1	1.7	0.2	(0.5)	0.0
	FY2010	1.2	4.6	0.5	(0.1)	0.1
	1st Half of FY2010	0.9	1.7	0.2	0.1	0.1
Ordinary Income	1st Half of FY2011	2.1	1.9	0.2	(0.5)	0.0
	FY2010	1.3	4.5	0.5	(0.3)	0.1
	1st Half of FY2010	1.0	1.7	0.3	0.1	0.1
Net Income and Loss	1st Half of FY2011	1.3	1.1	0.1	(0.5)	0.0
	FY2010	0.8	2.3	0.4	(0.3)	0.1
	1st Half of FY2010	0.6	1.2	0.2	0.0	0.1
R&D Expenses	1st Half of FY2011	0.9	0.4	-	0.0	-
	FY2010	2.0	0.9	-	0.0	0.0
	1st Half of FY2010	1.1	0.5	-	0.0	-
Depreciation of Property, Plant and Equipment	1st Half of FY2011	0.5	1.6	0.0	0.0	0.0
	FY2010	1.0	3.8	0.0	0.1	0.0
	1st Half of FY2010	0.5	1.8	0.0	0.0	0.0
Total Assets	End of 1st Half of FY2011	31.7	57.4	2.4	3.2	2.0
	FY2010	29.9	57.7	2.5	3.8	1.8
	End of 1st Half of FY2010	30.4	56.1	2.3	4.6	2.0
Net Assets	End of 1st Half of FY2011	25.9	38.6	1.7	2.7	1.4
	FY2010	25.0	38.6	1.5	3.2	1.4
	End of 1st Half of FY2010	24.8	37.5	1.7	3.8	1.4
Number of Employees	End of 1st Half of FY2011	567	1250	125	395	375
	FY2010	575	1219	125	419	333
	End of 1st Half of FY2010	580	1194	124	451	344

3 Forecasts for FY2011 Ending March 31, 2012

(Amounts less than ¥100 million are rounded down.)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %	Notes
Net sales	**405.0**	409.5	(4.5)	(1.1)	
Cost of sales	**150.0**	154.5	(4.5)	(3.0)	
Sales cost ratio	**37.0%**	37.7%			
Gross operatin profit	**255.0**	254.9	0.0	0.0	
SG & A expenses	**187.0**	178.3	8.6	4.8	
% of Net Sales	**46.2%**	43.6%			
Operating income	**68.0**	76.5	(8.5)	(11.2)	
Ordinary income	**68.0**	76.6	(8.6)	(11.3)	
Extraordinary income	**-**	0.6	(0.6)	(100.0)	
Extraordinary loss	**4.5**	13.2	(8.7)	(65.9)	
Net income	**37.5**	37.7	(0.2)	(0.7)	

(2) Sales Forecasts by Segments

[Billion yen]

	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %	Notes
Pharmaceuticals	**395.5**	400.2	(4.7)	(1.2)	
% Composition	**97.7%**	97.7%			
[Domestic]	**[371.0]**	[376.8]	[(5.8)]	[(1.6)]	
[Overseas]	**[24.5]**	[23.3]	[1.1]	[4.8]	
Other businesses	**9.5**	9.3	0.1	2.0	
% Composition	**2.3%**	2.3%			
[Domestic]	**[7.0]**	[6.9]	[0.0]	[1.2]	
[Overseas]	**[2.5]**	[2.3]	[0.1]	[4.4]	
Total	**405.0**	409.5	(4.5)	(1.1)	Overseas sales ratio FY2010: 6.3% FY2011estimation: 6.7%
% Composition	**100.0%**	100.0%			
[Domestic]	**[378.0]**	[383.7]	[(5.7)]	[(1.5)]	
[Overseas]	**[27.0]**	[25.7]	[1.2]	[4.8]	

(3) Forecasts of Cost of Sales and SG&A Expenses

[Billion yen]

	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %	Notes
Cost of sales	**150.0**	154.5	(4.5)	(3.0)	
Sales cost ratio	**37.0%**	37.7%			
SG & A expenses	**187.0**	178.3	8.6	4.8	
% of net sales	**46.2%**	43.6%			
R&D expenses	**69.0**	65.7	3.2	4.9	
% of Net sales	**17.0%**	16.1%			
Except R&D expens	**118.0**	112.6	5.3	4.8	
Labor cost	**51.5**	52.5	(1.0)	(1.9)	
Amortization of goodwill *	**10.0**	10.1	(0.1)	(1.5)	
Others	**56.5**	49.9	6.5	13.1	Increase in sales promotion expenses accompanied with launch of new products
Total labor cost	**89.0**	88.6	0.3	0.4	

*: Clear off 150.5 billion yen within 15 years.

(4) Sales Forecasts for Main Products [Billion yen]

	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %
Ethical drugs	**390.5**	394.7	(4.2)	(1.1)
Ethical drugs domestic sales	**358.0**	361.6	(3.6)	(1.0)
Remicade	**66.4**	60.4	6.0	10.0
Radicut	**23.7**	28.7	(4.9)	(17.4)
Ceredist	**18.1**	18.0	0.0	0.5
Anplag	**15.0**	16.4	(1.4)	(8.5)
Talion	**14.5**	13.4	1.1	8.3
Urso	**14.2**	15.3	(1.1)	(7.3)
Maintate	**13.4**	12.3	1.1	9.6
Kremezin *1	**12.2**	-	12.2	-
Depas	**10.8**	11.4	(0.5)	(5.1)
Venoglobulin IH	**10.2**	9.6	0.6	6.3
Herbesser	**8.6**	9.6	(0.9)	(10.0)
Tanatril	**8.2**	9.6	(1.4)	(15.1)
Liple	**6.1**	7.3	(1.1)	(15.7)
Sermion	**5.4**	6.3	(0.8)	(13.9)
Neuart	**5.1**	5.5	(0.4)	(7.7)
Omeprason	**4.0**	4.8	(0.7)	(16.2)
BIKEN Products [Vaccine]	**29.5**	29.6	0.0	(0.1)
Mearubik	**10.0**	12.2	(2.2)	(18.5)
JEVIK V	**8.5**	6.9	1.6	23.2
Influenza	**8.2**	7.1	1.1	15.8
Tanabe Seiyaku Hanbai Products *2	**17.3**	14.0	3.2	23.2
Ethical drugs overseas sales	**18.5**	21.3	(2.8)	(13.2)
Herbesser	**4.6**	4.6	0.0	(1.1)
Argatroban (Novastan)	**2.8**	3.4	(0.6)	(18.7)
Tanatril	**1.7**	1.8	0.0	(3.4)
Vaccine	**1.6**	1.3	0.2	20.1
Contracted manufacturing products *3	**8.0**	9.3	(1.3)	(14.7)
Lincensing Fee, etc.	**6.0**	2.4	3.5	145.7
OTC products	**5.0**	5.4	(0.4)	(8.0)
Total Pharmaceuticals	**395.5**	400.2	(4.7)	(1.2)

*1: In FY2010, Daiichi Sankyo sold Kremezin on consignment from MTPC. We recorded amount of money we sold Kremezin to Daiichi Sankyo in "ethical drugs domestic sales" in FY2010, however, we do not disclose this sales.

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*3: Active pharmaceutical ingredients and others ordered by other compnies.

(5) Forecast for Investment in Property, Plant and Equipment and Information System

[Billion yen]

	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %
Investment in property, plant and equipment/occuring basis	**7.7**	**10.1**	**(2.4)**	**(24.3)**
Investment in information systems/occuring basis	**1.0**	**0.8**	**0.1**	**19.3**

[Billion yen]

Major investment in property, plant and equipment in 2nd half of FY2011		Major investment in information system in 2nd half of FY2011	
Production Facilities	2.8	R&D Related Systems	0.4
Facilities & Equipment for R&D	1.9	Production Related Systems	0.1
Others	0.1	Others	0.1

(6) Forecasts for Depreciation Costs

[Billion yen]

	FY2011 Forecasts	FY2010 Actual	Increase (Decrease)	Change %
Property, plant and equipment	**12.2**	**11.3**	**0.8**	**7.5**
Intangible fixed assets	**1.0**	**1.0**	**0.0**	**(7.7)**

4 Five-Year Financial Data

Amounts less than ¥100 million are rounded down.

(1) Profit and Loss

[Billion yen]

	FY2007 Simple Sum	FY2008	FY2009	FY2010	1st Half of FY2011	Forecast for FY2011
Net sales	409.4	414.7	404.7	409.5	200.3	405.0
Cost of sales	150.5	158.1	147.8	154.5	74.4	150.0
Gross operation profit	258.8	256.5	256.9	254.9	125.9	255.0
SG&A expenses	186.4	184.8	195.4	178.3	89.8	187.0
R&D expenses	72.3	73.1	83.0	65.7	33.5	69.0
Operating income	72.4	71.6	61.4	76.5	36.0	68.0
Ordinary income	73.6	72.5	61.6	76.6	36.3	68.0
Extraordinaly income	1.9	1.2	0.0	0.6	-	-
Extraordinaly loss	20.3	25.7	10.7	13.2	3.2	4.5
Net income	31.9	26.5	30.2	37.7	19.9	37.5

(2) Balance Sheet

[Billion yen]

	End of FY2007	End of FY2008	End of FY2009	End of FY2010	End of 1st Half of FY2011
Total assets	807.2	810.7	796.8	818.7	815.0
Current assets	382.0	364.4	344.2	391.5	401.2
Fixed assets	425.2	446.3	452.6	427.1	413.8
Total liabilities	139.4	144.5	120.0	122.7	107.7
Current liabilities	89.4	89.1	77.7	87.7	75.9
Fixed liabilities	50.0	55.3	42.2	35.0	31.8
Net assets	667.8	666.2	676.8	695.9	707.2

③ Other Financial Data

[Billion yen]

	FY2007 Simple Sum	FY2008	FY2009	FY2010	1st Half of FY2011	Forecast for FY2011
Cash flows from operating activities	46.4	50.5	23.9	59.0	16.3	-
Cash flows from investing activities	(8.9)	(74.5)	(61.2)	(7.6)	(44.5)	-
Cash flows from financing activities	(9.0)	(15.9)	(17.1)	(15.4)	(8.6)	-
Investments in property, plant and equipmer	9.9	12.1	8.3	10.1	2.8	7.7
Investments for development of information systems	1.9	1.7	0.8	0.8	0.3	1.0
Depreciation costs	15.0	15.6	13.2	12.4	5.8	13.2
Equity ratio (%)	80.9	80.5	84.1	84.3	86.1	-
ROE (%)	4.9	4.1	4.6	5.5	5.7	-
Net income per share (¥)	50.12	47.28	53.91	67.27	35.58	66.84
Net assets per share (¥)	1,163.96	1,162.69	1,194.79	1,230.16	1,250.20	-

(4) Number of Employees

	End of FY2007	End of FY2008	End of FY2009	End of FY2010	End of 1st Half of FY2011	Forecast for End of FY2011
Consolidated	10,361	10,030	9,266	9,198	9,197	9,185
Non-consolodated	6,266	5,715	5,186	4,957	4,891	4,780

5 Quarterly Trend

(Amounts less than ¥100 million is rounded down.)

(1) Profit and Loss

[Billion yen]

	FY2010					FY2011		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2010 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Forecast for FY2011
Net sales	108.7	95.9	114.8	89.9	409.5	102.2	98.1	405.0
	26.6%	23.4%	28.0%	22.0%	100.0%	25.2%	24.2%	100.0%
[Domestic]	[102.0]	[88.9]	[108.9]	[83.8]	[383.7]	[95.7]	[91.4]	[378.0]
	[26.6%]	[23.2%]	[28.4%]	[21.8%]	[100.0%]	[25.3%]	[24.2%]	[100.0%]
[Overseas]	[6.7]	[6.9]	[5.9]	[6.1]	[25.7]	[6.5]	[6.6]	[27.0]
	[26.1%]	[27.1%]	[22.9%]	[23.8%]	[100.0%]	[24.3%]	[24.6%]	[100.0%]
Pharmaceuticals	106.0	93.8	112.5	87.8	400.2	99.7	95.6	395.5
	26.5%	23.4%	28.1%	22.0%	100.0%	25.2%	24.2%	100.0%
[Domestic]	[100.2]	[87.2]	[107.1]	[82.2]	[376.8]	[93.7]	[89.8]	[371.0]
	[26.6%]	[23.2%]	[28.4%]	[21.8%]	[100.0%]	[25.3%]	[24.2%]	[100.0%]
[Overseas]	[5.7]	[6.5]	[5.3]	[5.6]	[23.3]	[6.0]	[5.8]	[24.5]
	[24.8%]	[28.1%]	[22.9%]	[24.2%]	[100.0%]	[24.6%]	[23.8%]	[100.0%]
Others	2.7	2.0	2.3	2.1	9.3	2.5	2.4	9.5
	29.6%	22.5%	25.3%	22.6%	100.0%	26.4%	25.7%	100.0%
[Domestic]	[1.8]	[1.6]	[1.8]	[1.6]	[6.9]	[1.9]	[1.6]	[7.0]
	[26.4%]	[24.0%]	[26.2%]	[23.5%]	[100.0%]	[28.1%]	[23.2%]	[100.0%]
[Overseas]	[0.9]	[0.4]	[0.5]	[0.4]	[2.3]	[0.5]	[0.8]	[2.5]
	[39.0%]	[18.2%]	[22.8%]	[20.1%]	[100.0%]	[21.4%]	[32.5%]	[100.0%]
Cost of sales	41.3	36.5	44.5	32.1	154.5	37.3	37.0	150.0
Sales Cost Ratio	38.0%	38.1%	38.8%	35.7%	37.7%	36.5%	37.8%	37.0%
Gross operating profit	67.4	59.4	70.2	57.8	254.9	64.8	61.0	255.0
	26.5%	23.3%	27.6%	22.7%	100.0%	25.5%	23.9%	100.0%
SG & A expenses	40.8	45.8	41.5	50.1	178.3	42.1	47.7	187.0
	22.9%	25.7%	23.3%	28.1%	100.0%	22.5%	25.5%	100.0%
R&D expenses	15.9	16.5	15.1	18.1	65.7	15.7	17.8	69.0
	24.2%	25.1%	23.0%	27.7%	100.0%	22.8%	25.8%	100.0%
Except R&D expenses	24.9	29.2	26.4	31.9	112.6	26.4	29.8	118.0
	22.1%	26.0%	23.5%	28.4%	100.0%	22.4%	25.3%	100.0%
Labor costs	12.3	13.4	12.4	14.2	52.5	12.6	13.3	51.5
	23.5%	25.6%	23.7%	27.2%	100.0%	24.5%	25.8%	100.0%
Amortization of goodwill	2.5	2.5	2.5	2.5	10.1	2.5	2.5	10.0
	25.0%	25.0%	25.0%	25.0%	100.0%	25.3%	25.3%	100.0%
Others	10.0	13.2	11.5	15.1	49.9	11.2	14.0	56.5
	20.1%	26.6%	23.0%	30.3%	100.0%	20.0%	24.9%	100.0%
Operating income	26.5	13.5	28.7	7.7	76.5	22.7	13.3	68.0
	34.7%	17.7%	37.5%	10.1%	100.0%	33.4%	19.6%	100.0%
Ordinary income	26.7	13.6	28.9	7.2	76.6	22.9	13.3	68.0
	34.9%	17.8%	37.7%	9.5%	100.0%	33.8%	19.7%	100.0%
Net income	14.6	8.0	16.5	(1.5)	37.7	11.4	8.5	37.5
	38.9%	21.3%	43.9%	(4.0%)	100.0%	30.5%	22.8%	100.0%

The each figure (excluding Cost of Sales) in the lower displays the progress rate.

(2) Sales of Main Products

[Billion yen]

	FY2010					FY2011		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2010 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Forecast for FY2011
Ethical drugs	104.7	92.2	110.9	86.8	394.7	98.3	94.2	390.5
	26.5%	23.4%	28.1%	22.0%	100.0%	25.2%	24.1%	100.0%
Ethical drugs domestic sales	96.0	83.0	103.5	78.9	361.6	89.7	85.9	358.0
	26.6%	23.0%	28.6%	21.8%	100.0%	25.1%	24.0%	100.0%
Remicade	14.3	14.9	17.3	13.7	60.4	15.8	16.2	66.4
	23.8%	24.8%	28.8%	22.7%	100.0%	23.8%	24.4%	100.0%
Radicut	7.9	6.2	8.0	6.3	28.7	6.7	6.0	23.7
	27.8%	21.9%	28.2%	22.1%	100.0%	28.4%	25.5%	100.0%
Ceredist	4.8	4.1	5.1	3.9	18.0	4.6	4.2	18.1
	26.6%	23.0%	28.3%	22.0%	100.0%	25.6%	23.5%	100.0%
Anplag	4.5	3.7	4.7	3.4	16.4	4.0	3.6	15.0
	27.5%	22.8%	28.8%	20.9%	100.0%	27.2%	24.1%	100.0%
Talion	2.6	2.0	3.5	5.1	13.4	3.0	2.2	14.5
	19.8%	15.6%	26.5%	38.1%	100.0%	21.1%	15.5%	100.0%
Urso	4.1	3.5	4.2	3.3	15.3	3.7	3.4	14.2
	26.9%	23.3%	27.8%	22.0%	100.0%	26.6%	24.0%	100.0%
Maintate	3.2	2.7	3.4	2.8	12.3	3.4	3.1	13.4
	26.3%	22.2%	28.4%	23.1%	100.0%	25.2%	23.6%	100.0%
Kremezin	-	-	-	-	-	2.8	3.3	12.2
	-	-	-	-	-	23.3%	27.3%	100.0%
Depas	3.0	2.6	3.1	2.5	11.4	2.8	2.6	10.8
	27.0%	23.1%	27.7%	22.2%	100.0%	25.8%	24.3%	100.0%
Venoglubulin IH	2.3	2.1	2.8	2.1	9.6	2.4	2.5	10.2
	24.9%	22.4%	29.9%	22.7%	100.0%	24.4%	24.9%	100.0%
Herbesser	2.7	2.1	2.8	1.9	9.6	2.3	2.0	8.6
	28.1%	22.6%	29.3%	20.0%	100.0%	27.0%	23.5%	100.0%
Tanatril	2.7	2.2	2.7	1.9	9.6	2.2	2.0	8.2
	28.5%	23.2%	28.3%	20.0%	100.0%	27.7%	24.4%	100.0%
Liple	2.0	1.6	2.0	1.5	7.3	1.6	1.4	6.1
	27.7%	23.1%	27.7%	21.5%	100.0%	26.8%	24.1%	100.0%
Sermion	1.8	1.5	1.7	1.2	6.3	1.5	1.3	5.4
	28.4%	23.5%	27.8%	20.3%	100.0%	27.4%	24.5%	100.0%
Neuart	1.4	1.3	1.6	1.1	5.5	1.2	1.2	5.1
	26.1%	23.3%	30.1%	20.5%	100.0%	24.9%	24.9%	100.0%
Omeprazon	1.3	1.1	1.3	1.0	4.8	1.1	1.0	4.0
	28.3%	22.7%	28.5%	20.5%	100.0%	27.5%	25.2%	100.0%
BIKEN products [Vaccine]	7.7	7.3	9.2	5.2	29.6	7.0	8.0	29.5
	26.1%	24.8%	31.3%	17.8%	100.0%	23.8%	27.3%	100.0%
Mearubik	4.9	2.5	1.4	3.2	12.2	4.1	2.1	10.0
	40.6%	21.1%	11.6%	26.6%	100.0%	41.6%	21.1%	100.0%
JEBIK V	1.7	1.9	1.6	1.5	6.9	2.0	2.8	8.5
	25.6%	27.9%	23.9%	22.6%	100.0%	24.5%	32.8%	100.0%
Influenza	0.0	1.9	5.7	(0.5)	7.1	0.0	2.3	8.2
	0.0%	27.4%	80.2%	(7.6%)	100.0%	(0.1%)	28.4%	100.0%
Tanabe Seiyaku Hanbai products *1	2.8	2.5	4.7	3.9	14.0	4.3	3.8	17.3
	20.4%	18.1%	33.7%	27.9%	100.0%	25.1%	22.2%	100.0%
Ethical drugs overseas sales	5.6	5.6	5.0	4.9	21.3	4.6	4.4	18.5
	26.6%	26.4%	23.7%	23.3%	100.0%	25.3%	24.2%	100.0%
Herbesser	1.2	1.2	1.0	1.1	4.6	1.1	1.0	4.6
	25.9%	26.4%	23.4%	24.3%	100.0%	26.1%	23.9%	100.0%
Argatroban (Novastan)	1.0	0.8	0.8	0.7	3.4	0.9	0.6	2.8
	29.5%	23.5%	24.3%	22.8%	100.0%	35.1%	22.9%	100.0%
Tanatril	0.5	0.4	0.4	0.3	1.8	0.3	0.4	1.7
	30.0%	23.2%	27.0%	19.8%	100.0%	22.1%	27.3%	100.0%
Vaccine	0.2	0.4	0.2	0.4	1.3	0.4	0.4	1.6
	18.9%	30.0%	16.5%	34.6%	100.0%	29.0%	28.4%	100.0%
Contracted manufacturing products *2	2.6	2.5	1.9	2.2	9.3	2.4	2.3	8.0
	28.6%	27.0%	20.9%	23.5%	100.0%	30.6%	29.2%	100.0%
Lincensing fee, etc.	0.2	1.0	0.4	0.6	2.4	1.4	1.4	6.0
	11.3%	42.5%	17.6%	28.6%	100.0%	24.0%	24.4%	100.0%
OTC products	1.2	1.5	1.5	1.0	5.4	1.4	1.4	5.0
	23.7%	29.1%	28.2%	19.0%	100.0%	28.5%	29.2%	100.0%
Total pharmaceuticals	106.0	93.8	112.5	87.8	400.2	99.7	95.6	395.5
	26.5%	23.4%	28.1%	22.0%	100.0%	25.2%	24.2%	100.0%

The each figure in the lower displays the progress rate.

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2: Active pharmaceutical ingredients and others ordered by other companies.

6 State of New Product Development (As of Oct. 31, 2011)

1. Pipeline in Japan

(1) New Molecular Entities

Development code (Generic name)	Category (Indications)	Stage	Origin	Notes
MP-513 (Teneligliptin)	DPP4 Inhibitor (Type 2 Diabetes mellitus)	NDA filed (Aug. 2011)	In-house	
	(Type 2 Diabetes mellitus, Additional combination)	Phase3		
BK-4SP	Vaccine (Prophylaxis of pertussis, diphtheria, tetanus, and poliomyelitis)	Phase 3	The Research Foundation for Microbial Diseases of Osaka University	Co-development -The Research Foundation for Microbial Diseases of Osaka University
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 Diabetes mellitus)	Phase 3	In-house	
MP-214 (Cariprazine)	D3/D2 receptor antagonist (Schizophrenia)	Phase 2	Hungary: Gedeon-Richter	
MP-435	C5a receptor antagonist (Rheumatoid arthritis)	Phase 2	In-house	
MT-4666	α7nAChR agonist (Alzheimer's disease)	Phase 1	US: EnVivo Pharmaceuticals	

(2) Additional Indications

Development code/Product name (Generic name)	Category (Indications)	Stage	Origin	Notes
Venoglobulin IH (Polyethylene glycol treated human normal immunogloblin)	Human immunoglobulin G (IgG2 deficiency)	sNDA filed (Dec. 1997)	In-house	
	(Systemic scleroderma)	Phase 3		
Modiodal (Modafinil)	Psychoneurotic agent (Obstructive sleep apnea syndrome)	sNDA filed (May 2010)	US: Cephalon	Co-development -Alfresa Pharma
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Phase 3	In-house	
Maintate (Bisoprolol)	Selective β 1 blocker (Chronic atrial fibrillation)	Phase 3	In-house	
Talion (Bepotastine)	Selective histamine H1 receptor antagonist・anti-allergic agent (Pediatric allergic rhinitis)	Phase 3	Japan: Ube Industries	
Cholebine (Colestimide(JAN))	Bile acid signal regulation (Type 2 diabetes mellitus)	Phase 2	In-house	
	Non-absorbed phosphate binder (Hyperphosphatemia)	Phase 1		

*: Orphan drug designated

2. Pipeline Overseas

(1) New Molecular Entities

Development code (Generic name)	Category (Indications)	Region	Stage	Origin	Notes
LIVALO (Pitavastatin)	HMG-CoA reductase inhibitor (Primary hyperlipidemia, mixed dyslipidemia)	Indonesia	NDA filed (Jun. 2010)	Japan: Kowa	Filed by Tanabe Indonesia
MCI-196 (Colestilan(INN))	Non-absorbed phosphate binder (Hyperphosphatemia)	Europe	MAA filed (Aug. 2011)	In-house	
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Japan:Kureha	
MT-2832 (Lunacalcipol)	Vitamin D analog (Secondary hyperparathyroidism)	US, Canada	Phase 2	Canada: Cytochroma	
MCI-186 (Edaravone)	Free radical scavenger (Acute ischemic stroke)	Europe	Phase 2	In-house	
MP-513 (Teneligliptin)	DPP4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house	
		US	Phase 1		
GB-1057 (Human serum albumin[recombinant])	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house	
TA-8995	CETP inhibitor (Dyslipidemia)	Europe	Phase 1	In-house	
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house	
MP-136	PPAR alpha agonist (Dyslipidemia)	Europe	Phase 1	In-house	
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Europe	Phase 1	In-house	
MP-157	Angiotensin Type2 Receptor agonist (Hypertention)	Europe	Phase 1	In-house	
MT-1303	Sphingosine-1-phosphate receptor functiona antagonist (Multiple sclerosis)	Europe	Phase 1	In-house	
MT-7716	NOP receptor agonist (Alcohol-use disorder)	US	Phase 1	In-house	

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	US	NDA Filed (June, 2011)	US: Vivus
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 Diabetes mellitus)	US, Europe	Phase 3	US: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
	(Obesity)	US, Europe	Phase 2	
T-0047 (Firategrast)	Cell adhesion inhibitor [α4β7/α4β1 inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK:GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US:MediciNova
MKC-231	Neurogenesis enhancer (Depression/anxiety)	US	Phase 2	US:BrainCells
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
MKC-733	5-HT3 receptor agonist (Gastroesophageal reflux disease)	US	Phase 2	US: Edusa Pharmaceuticals
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase1	France:Negma (Sidem)
TT-138	β3 receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US:MediciNova
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase1	Japan: Maruho

4. Changes Since Previous Announcement on July 29, 2011

(1) In-house Development

Development code/Product name (Generic name)	Category (Indications)	Region	As of Jul 29, 2011	As of Oct 31, 2011
FTY720 (Fingolimod)	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis*)	Japan	NDA filed (Dec. 2010)	Approved (Sep. 2011)
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	Japan	NDA filed (Jan. 2011)	Approved (Sep. 2011)
Venoglobulin IH (Polyethylene glycol treated human normal immunogloblin)	Human immunoglobulin G (Generalized myasthenia gravis*)	Japan	sNDA filed (Dec. 2010)	Approved (Sep. 2011)
Remicade (Infliximab[recombinant])	Anti-TNFα monoclonal antibody (Crohn's disease*: dose escalation)	Japan	sNDA filed (Dec. 2010)	Approved (Aug. 2011)
MCI-196 (Colestilan(INN))	Non-absorbed phosphate binder (Hyperphosphatemia)	Europe	Phase 3	MAA filed (Aug. 2011)
		US	Phase 3	Discontinued
MP-513 (Teneligliptin)	DPP4 Inhibitor (Type 2 Diabetes mellitus)	Japan	Phase 3	NDA filed (Aug. 2011)
Maintate (Bisoprolol)	Selective β 1 blocker (Chronic atrial fibrillation)	Japan	-	Phase 3
Talion (Bepotastine)	Selective histamine H1 receptor antagonist・ anti-allergic agent (Pediatric allergic rhinitis)	Japan	-	Phase 3
MT-7716	NOP receptor agonist (Alcohol-use disorder)	US	-	Phase 1

*: Orphan drug designated

(2) Licensing-out

Development code (Generic name)	Category (Indications)		As of Jul 29, 2011	As of Oct 31, 2011
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Korea	Filed (Jan. 2011)	Approved (Aug. 2011)

5. Additional Information for State of New Product Development

(1) New Molecular Entities in Japan

Development code (Generic name)	Information
MP-513 (Teneligliptin)	MP-513 is developed for the treatment of type-2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP4), thus accelerates the insulin secretion after meal intake. NDA was filed in August 2011. Additional combination trials are on going.
BK-4SP	Diphtheria toxoid- t etanus toxoid- b ordetella pertussis antigen-inactivated poliovirus combined vaccine. Co-development with the Research Foundation for Microbial Diseases of Osaka University. Clinical stage is Phase 3.
MP-214 (Cariprazine)	MP-214 is a dopamine D3/D2 receptor antagonist, licensed from Gedeon-Richter (Hungary). Clinical stage is Phase 2 for schizophrenia.
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. Clinical stage is Phase 3 for type2 diabetes mellitus.
MP-435	MP-435 is a C5a (complement factor) receptor antagonist which modulates the immune system. Clinical stage is Phase 2 for Rheumatoid arthritis.
MT-4666	MT-4666 is an α7 nACh receptor agonist, licensed from EnVivo pharmaceuticals Inc. (US). Clinical stage is Phase 1 for Alzheimer's disease.

(2) Additional Indications in Japan

Development code/Product name (Generic name)	Information
Venoglobulin IH (Polyethylene glycol treated human normal immunogloblin)	(IgG2 deficiency) sNDA has been filed.
	(Diffuse systemic scleroderma) Clinical research in Japan demonstrated IV-IG was effective in improvement of skin manifestation, a main factor of systemic scleroderma. Efficacy of IV-IG was also reported in overseas studies. Clinical stage is Phase 3.
Modiodal (Modafinil)	(Obstructive sleep apnea) sNDA was filed by Alfresa Pharma Corp. in May 2008. As a result of the consultation with PMDA, additional data were required. The additional data were submited in May 2010.
Radicut (Edaravone)	(Amyotrophic lateral sclerosis [Orphan drug designated in June, 2005]) Clinical stage is Phase 3. Additional clinical study is in preparation.
Maintate (Bisoprolol)	(Chronic atrial fibrillation) The development was requested by the academic society. Dose-finding trial is now conducted. Clinical stage is Phase 3.
Talion (Bepotastine)	(Pediatric allergic rhinitis) We lauched this drug as an anti-allergic agent for adult in 2000. Clinical stage is Phase 3 for pediatric allergic rhinitis.
Cholebine (Colestimide(JAN))	(Type 2 diabetes mellitus) Clinical stage is Phase 2.
	(Hyperphosphatemia) Clinical stage is Phase 1.

(3) New Molecular Entities Overseas

Development code/Product name (Generic name)	Information
LIVALO (Pitavastatin)	LIVALO is HMG-CoA reductase inhibitor, licensed from Kowa (Japan) in August 2009. NDA has been filed in Indonesia by Tanabe Indonesia. It has been marketed by Kowa in Japan under the brand name, LIVALO®.
MCI-196 (Colestilan(INN))	MCI-196 is anion-exchange resin, and has been developed for the treatment of hyperphosphatemia in patients on dialysis. MAA was filed in Europe in Aug. 2011. Filing is discontinued in the US. It has been marketed in Japan for the treatment of hypercholesterolemia, under the brand name of CHOLEBINE®.
MP-146	MP-146 is spherical carbon adsorbent, licensed from KUREHA CORPORATION (Japan) in November 2006. Clinical stage is Phase 3 for Chronic Kidney Disease patients in Europe, North America and Latin America. It had been marketed by Daiichi Sankyo Co. Ltd. in Japan from 1991 under the brand name, KREMEZIN®. In April 2011, Mitsubishi Tanabe Pharma Corporation has succeeded its marketing from Daiichi Sankyo.
MT-2832 (Lunacalcipol)	MT-2832 was licensed from Cytochroma (Canada) in July 2008. MT-2832 is a strong activator of the vitamin D signaling pathway and has a resistance characteristics to CYP24, intracellular enzyme responsible for catabolism of Vitamin D hormones. Clinical stage is Phase 2 for secondary hyperparathyroidism in patients with chronic kidney disease in Canada and the US.
MCI-186 (Edaravone)	MCI-186 is the world's first cerebral neuroprotectant (free radical scavenger). Clinical stage in Europe is Phase 2 for the acute ischemic stroke. It has been marketed in Japan under the brand name, Radicut®.
MP-513 (Teneligliptin)	MP-513 is developed for the treatment of type-2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP4), thus accelerates the insulin secretion after meal intake. Clinical stages in the US and Europe are Phase1 and Phase 2, respectively.
GB-1057 (Human serum albumin [recombinant])	GB-1057 is a recombinant human serum albumin. Clinical stage is Phase 1 as a stabilizing agent in the US.
TA-8995	TA-8995 is a CETP inhibitor that has HDL-C raising and LDL-C lowering effects. Clinical stage is Phase 1 in Europe.
MP-124	MP-124 is a PARP inhibitor that has neuroprotective effect. Clinical stage in the US and Canada are Phase 1 for acute ischemic stroke.
MP-136	MP-136 is a PPAR alpha agonist. Clinical stage is Phase 1 in Europe for dyslipidemia.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist. Clinical stage is Phase 1 in Europe for hypertension.
MP-157	MP-157 is a angiotensin type2 receptor agonist. Clinical stage is Phase 1 in Europe for hypertention.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist. Clinical stage is Phase1 in Europe for multiple sclerosis as a succesor of Imusera..
MT-7716	MT-7716 is a NOP receptor agonist. Clinical stage is Phase1 in the US for Alcohol-use disorder (abuse and alcoholism).

(4) Licensing-out

Development code (Generic name)	Information
TA-1790 (Avanafil)	TA-1790 is created for the treatment of erectile dysfunction by Mitsubishi Tanabe Pharma, which is expected to have a quick onset and fewer side effects. NDA was filed by Vivus in the US in June 2011. JW Pharmaceutical obtained its approval in Korea in August 2011.
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. Phase 3 clinical trials in type2 diabetes mellitus in Europe and the US are underway by Johnson & Johnson Pharmaceutical Reseach & Development. Phase 2 clinical trials in obesity in Europe and the US are completed.
T-0047 (Firategrast)	T-0047 inhibits the cell adhesion and cell migration processes of white blood cells in inflammatory region. Phase 2 trial is conducted by GSK in Europe etc.
MKC-242	MKC-242 is a serotonin 1A receptor agonist, used to treat psychiatric disorders such as anxiety and depression. This compound is expected to reveal rapid onset with low possibility of dependency. Medici Nova (US) is conducting Phase 2 clinical trial for insomnia.
MKC-231	MKC-231 is a neurogenesis enhancer. Phase 2 study in major depression is underway by BrainCells(US).
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscle. Clinical trial stage in Japan is Phase 2 by Senju Pharmaceutical.
MT-210	MP-210 is a 5-HT2A/ Sigma 2 receptor antagonist. Clinical trial stage is Phase 2 in Europe by Cyrenaic (France).
MKC-733	MKC-733 modulates gastrointestinal motility by agonising serotonin 5-HT3 receptors. In the US, Edusa Pharmaceuticals is conducting a phase 2 clinical trial in patients with gastroesophageal reflux disease at night.
sTU-199 (Tenatoprazole)	sTU-199 is an isomer of TU-199, developed in Japan, and licensed to Negma (France). Pharmacokinetic/pharmacodynamic results from Phase 1 clinical trials in Europe and the US demonstrated that sTU-199 controlled gastric acid secretion at nighttime in patients receiving this compound once-daily, with the long half-life. It is expected that this compound could reveal rapid improvement for non-erosive reflux disease. Sidem Pharma, a subsidiary of Negma, is conducting phase 1 trial for gastroesophageal reflux dsease in Europe.
TT-138	TT-138 is a β3 receptor agonist used to treat pollakiuria and urinary incontinence. Phase 1 study is conducted by Medici Nova in the US.
TA-7906	TA-7906 is a PDE4 inhibitor. Clinical trial stage is Phase1 for the treatment of atopic dermatitis in Japan by Maruho.

7 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of 1st Half of FY2011	End of FY2010	Increase (Decrease)	Notes
Consolidated subsidiaries	**28**	28	-	
Non-consolidated subsidiaries	**3**	3	-	
Affiliated companies	**3**	3	-	
Total	**34**	34	-	

(2) Consolidated Subsidiaries [As of September 30, 2011]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Benesis Corporation	3,000	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
2	Mitsubishi Tanabe Pharma Factory Ltd.	1,130	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals and related products
3	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KRW 2,100,000,000.00	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
4	Mitsubishi Pharma (Guangzhou) Co., Ltd.	US$12,000,000	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
5	Tianjin Tanabe Seiyaku Co., Ltd.	US$12,000,000	66.7	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
6	Yoshitomiyakuhin Corporation	385	100.0	[-]	End of Mar.	Provision of information about pharmaceuticals
7	MP-Logistics Corporation	95	65.0	[-]	End of Mar.	Distribution, warehouse operations
8	BIPHA CORPORATION	7,500	51.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
9	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	400	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
10	Tanabe Seiyaku Hanbai., Ltd.	169	92.9	[7.9]	End of Mar.	Sale of generic pharmaceuticals and related products
11	Tanabe R&D Service Co., Ltd.	44	100.0	[-]	End of Mar.	Support of R&D regarding pharmaceuticals
12	Tanabe Total Service Co., Ltd.	90	100.0	[-]	End of Mar.	Real estate management and etc.
13	MP Healthcare Venture Management, Inc.	US$100	65.0	[-]	End of Dec.	Investments in bio-ventures
14	Mitsubishi Tanabe Pharma Holdings America, Inc.	US$166	100.0	[-]	End of Dec.	Management of group companies in US
15	Mitsubishi Tanabe Pharma Development America, Inc.	US$100	100.0	[100.0]	End of Dec.	R&D of pharmaceuticals
16	Tanabe Research Laboratories U.S.A., Inc.	US$3,000,000	100.0	[100.0]	End of Dec.	R&D of pharmaceuticals
17	Tanabe U.S.A., Inc.	US$1,400,000	100.0	[100.0]	End of Dec.	Sale of chemicals
18	Mitsubishi Tanabe Pharma America, Inc.	US$100	100.0	[100.0]	End of Dec.	Sale of pharmaceuticals
19	Mitsubishi Pharma Research & Development (Beijing) Co., Ltd.	US$1,000,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
20	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0	[-]	End of Dec.	Sale of pharmaceuticals
21	Taiwan Tanabe Seiyaku Co., Ltd.	NT$90,000,000.00	65.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
22	Tai Tien Pharmaceuticals Co., Ltd.	NT$20,000,000.00	65.0	[-]	End of Dec.	Sale of pharmaceuticals
23	P.T. Tanabe Indonesia	US$2,500,000	99.6	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
24	Mitsubishi Pharma Europe Ltd.	£4,632,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
25	Mitsubishi Pharma Deutschland GmbH	EUR 25,000	100.0	[100.0]	End of Dec.	Sale of pharmaceuticals
26	Tanabe Europe N.V.	EUR 260,330	100.0	[-]	End of Dec.	Sale of chemicals

Note: Aside from the companies mentioned above, there are two consolidated companies under the liquidations.

(3) Non-consolidated Subsidiaries Accounted for by the Equity Method [As of September 30, 2011]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Choseido Pharmaceutical Co.,Ltd.	340	52.5	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
2	Hoshienu Pharmaceutical Co.,Ltd.	75	52.5	[52.5]	End of Mar.	Manufacture and sale of pharmaceuticals

(4) Affiliated Companies Accounted for by the Equity Method [As of September 30, 2011]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	API Corporation	4,000	47.7	[-]	End of Mar.	Manufacture and sale of API
2	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	The End of September, 2011	The End of March, 2011
Issued	**561,417,916**	561,417,916
The company's own shares at the end of the period	**353,627**	353,152
Number of shares outstanding at the end of the period	**561,064,289**	561,064,764
Average number of the company's own share	**353,448**	307,141
Average number of shares outstanding	**561,064,468**	561,110,775

(2) Status of Major Shareholders

Rank	Name of Shareholders	The End of September, 2011		The End of March, 2011		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	The Master Trust of Japan, Ltd.	25,298	4.51%	2	25,490	4.54%
3	Japan Trustee Services Bank, Ltd.	21,431	3.82%	3	17,169	3.06%
4	Nippon Life Insurance Company	15,082	2.69%	4	15,875	2.83%
5	Nipro Corporation	7,642	1.36%	5	7,642	1.36%
6	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	6	7,254	1.29%
7	JP Morgan Chase Bank, N.A., 385147	7,100	1.26%	8	7,100	1.26%
8	Goldman Sachs & Company Regular Account	5,625	1.00%	7	7,116	1.27%
9	Tokyo Marine & Nichido Fire Insurance Co., Ltd.	4,958	0.88%	9	5,218	0.93%
10	Pershing-Div. of DLJ Secs. Corp.	4,735	0.84%	10	4,355	0.78%

(3) Ownership and Distribution of Shares

	The End of September, 2011			The End of March, 2010		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial Institutions	61	92,092	16.41%	62	90,522	16.13%
Foreign Corporations and Others	392	98,783	17.60%	391	100,839	17.97%
Individuals and Others	11,226	25,844	4.60%	11,460	26,104	4.65%
Other Corporations	281	342,632	61.04%	284	342,679	61.05%
Securities Firms	33	1,943	0.35%	38	1,148	0.20%
Total	11,993	561,296	100.00%	12,235	561,293	100.00%
Less than Trading Unit	-	121	-	-	124	-

* The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stock (353 thousands shares at the end of September, 2011 and 353 thousands shares at the end of March, 2011)

(4) Trend of Divinded and Stock Price

	FY2007 *1	FY2008 *2	FY2009 *2	FY2010 *2	1st Half of FY2011*2	FY2011 Estimate *2
Dividends per Share (Yen)	26	28	28	28	15	30
Dividend Payout Ratio(%)	44.0	43.0	39.0	32.9	33.7	35.4
Stock Price at end of FY	1,161	971	1,320	1,350	1,441	-
Market Capitalization (Billion Yen)	6,518	5,451	7,410	7,579	8,090	-

*1: The interim dividends of the former Tanabe Seiyaku (¥13) and the year-end dividends of Mitsubishi Tanabe Pharma (¥13) are used for the FY2007 dividends. The dividend payout ratio is calculated using Mitsubishi Tanabe Pharma's net income for the second half of the fiscal year (less amortization of goodwill) and Mitsubishi Tanabe Pharma's year-end dividends.

*2: The dividend payout ratio is calculated using Mitsubishi Tanabe Pharma's net income for the fiscal year (less amortization of goodwill) and annual dividends.

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNF α monoclonal antibody (Treatment of rheumatoid arthritis (RA), active Crohn's disease(CD), Behcet's disease with refractory uveoretinitis, psoriasis and ankylosing spondylitis, moderate to severe ulcerative colitis)
Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for eight weeks with a single administration. It has indications for the treatment of RA, CD, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis. In addtion, in 2009 and August 2011, changes in usage/dosage were approved for RA, and CD, respectively. Origin: Jannsen Biotech			
Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)
Radicut is the world's first brain protecting agent (free radical scavemger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administrated for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was approved in January and launched in May 2010.			
Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration
Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist, developed by Tanabe, is the world's first oral TRH derivative drug. An additional formulation, orally disintegrating tablets, was approved in June and launched in October 2009.			
Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT2 blocker (Anti-platelet agent)
Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as ulcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of collateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels. The downsized tablet which is convenient for elderly patients was approved in August 2007.			
Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders
Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets, was approved in March and launched in July 2007. Origin: Ube Industries			
Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions
Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in human body. Urso has effects of hapatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.			
Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β1 antagonist (Treatment of hypertension, angina pectoris, and arrhythmias)
Maintate is a representative β -blocker used in more than 85 countries around the world. It exhibits high selectivity for β 1 receptor and excellent phamacokinetics profiles. It has high efficacy and safety, and there is evidence for its cardioprotective action. Origin: Merck KGaA			
Kremezin	Launch: Apr. 2011	Category	Agent for treatment of Chronic renal failure
Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April, 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC. Origin, Manufacturer and distributor: Kureha			
Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent
Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.			

Venoglobulin IH (Human immunoglobulin)	Launch: Jan. 1992	Category	Plasma derivatives

Venoglobulin IH is intravenous human immunoglobulin derived from donated plasma in Japan. It shows high efficacy on serious infectious diseases in combined administration with anti-bacterial agent due to its opsonic, immuno-bacteriolytic and antibody-dependent cytotoxic effects and neutralizing effects on toxics and viruses. In October 2010 and September 2011, the indications for improvement of muscle weakness associated with polymyositis or dermatomyositis and generalized myasthenia gravis (only in case of insufficient response to steroids or immunosuppressants) were added, respectively. It is expected to be a new treatment option for the diseases that contribute better QOL for patients.

Herbesser (Diltiazem)	Launch: Feb. 1974	Category	Calcium antagonist (Treatment of angina pectoris and hypertension)

Herbesser is a representative calcium antagonist that is used in more than 110 countries around the world. In addition to a blood pressure lowering effect, it has a cardioprotective action in patients with hypertension or angina pectoris by reducing the cardiac load through a heart rate lowering effect and by increasing the oxygen supply through a coronary vasodilating effect.

Tanatril (Imidapril)	Launch: Dec. 1993	Category	ACE Inhibitor (Treatment of hypertension)

Tanatril shows excellent blood pressure control with effective organ protection as well as minimal incidence of dry cough, a common side effect of ACE inhibitors. With the approval of an additional indication in 2002, it became the first drug in Japan approved for diabetic nephropathy with type I diabetes mellitus.

Liple (Arprostadil)	Launch: Nov. 1988	Category	Agent for treatment for Chronic arterial occlusion / Circulatory disturbance (PGE1)

Liple, the world's first DDS (Drug Delivery System) agent of intravenous PGE1, improves the peripheral circulatory disturbance and skin ulcer in chronic arterial occlusive disease and diabetes by its direct vasodilating effects. DDS maximizes the therapeutic effects and simutaneously minimizes the adverse effects of PGE1.

Sermion (Nicergoline)	Launch: Jun. 1988	Category	Cerebral circulation and metabolism ameliorator

Sermion ameliorates blood flow and metabolism in the brain. It is used to treat sequela of cerebral infarction. In 1998, its effectiveness was confirmed in a reevaluation by the Ministry of Health and Welfare in Japan. In "the treatment guidelines for strokes in 2009," Sermion was recommended as a treatment drug for chronic cerebral infarction.
Origin: Pfizer

Neuart (Anti-thrombin III)	Launch: Jun. 1987	Category	Plasma derivatives (Anticoagulant agent)

Neuart is highly purified human anti-thrombin III derived from donated plasma in Japan. It shows strong anticoagulant effects in the treatment of DIC patients by inhibiting various kinds of activated serine protease including thrombin.

Omeprazon (Omeprazole)	Launch: Apr. 1991	Category	Proton pump inhibitor (Antiulcerogenic agent)

Omeprazon is the world's first proton pump inhibitor that suppresses gastric acid secretion. It strongly and sustainably blocks the final step in gastric acid production results in reducing gastric acidity. Omeprazon has excellent efficacy for gastric ulcer, duodenal ulcer and reflux esophagitis. Additional indications for non-erosive reflux disease (NERD) and secondary eradication of Hellicobacter pylori were approved in May and August 2007, respectively.
Origin: AstraZeneca

Mearubik (Live Attenuated Measles and Rubella Vaccine)	Launch: Dec. 2005	Category	Prevention of measles and rubella

Mearubik is the combination vaccine for measles and rubella, and children are able to receive both measles and rubella shot at a time with Mearubik. It is expected to contribute enhancement of immunization rate for measles and rubella in Japan.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

JEBIK V (Cell Culture-derived Japanese Encephalitis Vaccine)	Launch: Jan. 2009	Category	Prevention of Japanese encephalitis

JEBIK V is a freeze-dried preparation containing inactivated Japanese encephalitis virus derived from Vero cells which were used in the manufacturing process as a host to increase the virus. A freeze-dried prepared vaccine is available in routine vaccination. Accordingly, it is expected to increase in number of vaccinated persons.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

News Releases

The major news releases after April, 2011 are as follows.
Please refer to the Company's website for the details. (http://www.mt-pharma.co.jp/e/index.php)

Date	Contents
April 11, 2011	Impact of the Great East Japan Earthquake (3rd Notice)
April 27, 2011	Summary of the Quality Control Incident
April 27, 2011	Partial Return of Executive Compensation
May 10, 2011	Partial Amendment of the Articles of Incorporation
May 20, 2011	Approval for Additional Indication for selective β1 antagonist, MAINTATE Tablets 0.625, 2.5, and 5 and Launch of MAINTATE Tablets 0.625
May 20, 2011	Approval for Additional Indications for the Selective Antithrombin Agents,Novastan HI Injection 10 mg/2mL
May 20, 2011	Approval for Additional Indication of Anti-D Human Immunoglobulin I.M.1000-BENESIS (Dry anti-Rho(D) Immune Human Globulin)
May 27, 2011	Launch of Anti-allergy Agent, Bepotastine Besilate in China and Indonesia
June 2, 2011	AZANIN Tablets 50mg, Immunosuppressant Approval for Additional Indication for Refractory Rheumatic Diseases
June 17, 2011	Notice of a basic agreement between the Japanese Red Cross Society and Mitsubishi Tanabe Pharma Corporation regarding the commencement of discussions about the integration of their plasma fractionation operations
June 24, 2011	Notice of the Launch of Generic Drugs *
July 1, 2011	Approval for "SIMPONI Subcutaneous Injection 50mg Syringe(Generic Name: Golimumab)" for Treatment of Rheumatoid Arthritis
July 19, 2011	Notice Regarding a Business Suspension Order for the Ashikaga Plant of Mitsubishi Tanabe Pharma Factory Ltd. and a Business Improvement Order for Mitsubishi Tanabe Pharma Corporation
July 21, 2011	The NHI Drug Price Listing and Launch of an Anti-depressant, Lexapro 10mg
August 17, 2011	Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal-Antibody Approval for a Partial Change of Dosage and Usage in Crohn's Disease
August 22, 2011	Mitsubishi Tanabe Pharma Prevails in U.S. Argatroban Patent Litigation
September 1, 2011	New Drug Application Filed in Japan for MP-513 a Type 2 Diabetes Treatment
September 15, 2011	Launch of "SIMPONI (golimumab) Subcutaneous Injection 50mg Syringe" A Treatment of Rheumatoid Arthritis
September 26, 2011	Approval for "IMUSERA Capsules 0.5mg" Japan's First Once-Daily Oral Dosing Multiple Sclerosis Treatment
September 26, 2011	Approval for TELAVIC 250mg Tablet Novel Mode of Action for Chronic Hepatitis C Treatment
September 26, 2011	Approval for Additional Indication of Generalized Myasthenia Gravis Venoglobulin IH 5% for Intravenous Injection,a Human Immunoglobulin Preparation Derived from Donated Plasma
October 14, 2011	Toray, Mitsubishi Tanabe Pharma Reach North American License Agreement on Antipruritic Agent, TRK-820
October 17, 2011	Formulation of Medium-Term Management Plan 11-15 New Value Creation

*: Only in Japanese